Research
Hormonal
Glucagon emergency kits (subcutaneous, intramuscular, or intranasal) are the standard of care for rapidly reversing severe hypoglycaemia in Type 1 Diabetes, with newer formulations offering faster resolution and ease of use.
If you have Type 1 Diabetes, keep a glucagon emergency kit (like Baqsimi or Zegalogue) accessible. In a severe low blood sugar emergency where the person cannot eat or drink, this medication rapidly raises blood sugar by signaling the liver to release glucose. Newer nasal and auto-injector versions are easier to use and work faster than older injection kits.
StrongSupportsHIGH confidence
intramuscular glucagon is well established in rescue of hypoglycaemia... glucagon emergency kits simply involve reconstitution of glucagon powder, which can be injected into the patient’s leg or abdomen (32, 55). Moreover, a ready-to use autoinjector preparation termed “Zegalogue” has recently gained FDA approval for management of hypoglycaemia (33)... the ready-to-use i.n. formulation has been proposed to lead to resolution of hypoglycaemia up to four times faster than injectable glucagon kits (59).
Why this rating
Supported by FDA approvals and established clinical guidelines referenced in the text.
Source
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty et al. · Frontiers in Endocrinology · 2021
DOI 10.3389/fendo.2021.689678
narrative_reviewCited 66×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →